Edition:
United States

Solid Biosciences Inc (SLDB.OQ)

SLDB.OQ on NASDAQ Stock Exchange Global Select Market

49.72USD
12:00pm EDT
Change (% chg)

$-1.50 (-2.93%)
Prev Close
$51.22
Open
$50.95
Day's High
$52.54
Day's Low
$48.98
Volume
13,307
Avg. Vol
74,160
52-wk High
$54.51
52-wk Low
$6.83

Chart for

About

Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies... (more)

Overall

Beta: --
Market Cap(Mil.): $1,814.85
Shares Outstanding(Mil.): 35.43
Dividend: --
Yield (%): --

Financials

  SLDB.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -1.82 -- --
ROI: -- 1.50 12.72
ROE: -- 0.19 14.85

BRIEF-Boxer Capital Reports 6.2 Pct Passive Stake In Solid Biosciences

* BOXER CAPITAL, LLC REPORTS 6.2 PERCENT PASSIVE STAKE IN SOLID BIOSCIENCES INC AS OF MAY 9 - SEC FILING Source text: (https://bit.ly/2GwS8zg) Further company coverage:

May 18 2018

BRIEF-Solid Biosciences Reports Quarterly Loss Per Share Of $0.54

* SOLID BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 10 2018

BRIEF-Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy

* SOLID BIOSCIENCES PROVIDES UPDATE ON SGT-001 CLINICAL DEVELOPMENT PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY

Apr 18 2018

BRIEF-Solid Biosciences Reports Full Year 2017 Financial Results And Provides Corporate Update

* SOLID BIOSCIENCES REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 29 2018

Earnings vs. Estimates